Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Taysha Gene Therapies (TSHA) Gains from Investment Securities (2022 - 2025)

Historic Gains from Investment Securities for Taysha Gene Therapies (TSHA) over the last 4 years, with Q3 2025 value amounting to $699000.0.

  • Taysha Gene Therapies' Gains from Investment Securities fell 7217.06% to $699000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$64.7 million, marking a year-over-year decrease of 267647.12%. This contributed to the annual value of $3.7 million for FY2024, which is 4832.79% down from last year.
  • Latest data reveals that Taysha Gene Therapies reported Gains from Investment Securities of $699000.0 as of Q3 2025, which was down 7217.06% from $3.5 million recorded in Q2 2025.
  • In the past 5 years, Taysha Gene Therapies' Gains from Investment Securities ranged from a high of $18.6 million in Q1 2022 and a low of -$65.7 million during Q4 2023
  • Over the past 4 years, Taysha Gene Therapies' median Gains from Investment Securities value was $2.6 million (recorded in 2023), while the average stood at -$856297.7.
  • Examining YoY changes over the last 5 years, Taysha Gene Therapies' Gains from Investment Securities showed a top increase of 72887.42% in 2023 and a maximum decrease of 1665869.02% in 2023.
  • Over the past 4 years, Taysha Gene Therapies' Gains from Investment Securities (Quarter) stood at $397000.0 in 2022, then crashed by 16658.69% to -$65.7 million in 2023, then soared by 99.89% to -$72000.0 in 2024, then skyrocketed by 1070.83% to $699000.0 in 2025.
  • Its Gains from Investment Securities stands at $699000.0 for Q3 2025, versus $3.5 million for Q2 2025 and $4.7 million for Q1 2025.